Last €4.52 EUR
Change Today +0.045 / 1.01%
Volume 0.0
APS On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 1:19 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

ariad pharmaceuticals inc (APS) Snapshot

Open
€4.46
Previous Close
€4.47
Day High
€4.57
Day Low
€4.42
52 Week High
09/20/13 - €15.72
52 Week Low
10/31/13 - €1.57
Market Cap
844.9M
Average Volume 10 Days
6.3K
EPS TTM
--
Shares Outstanding
187.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARIAD PHARMACEUTICALS INC (APS)

ariad pharmaceuticals inc (APS) Related Businessweek News

No Related Businessweek News Found

ariad pharmaceuticals inc (APS) Details

ARIAD Pharmaceuticals, Inc., an oncology company, is engaged in the discovery, development, and commercialization of medicines for cancer patients. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States and Europe. The company is also developing Iclusig for other blood cancers and solid tumors, such as gastrointestinal stromal tumors, acute myeloid leukemia, and certain forms of non-small cell lung cancer; and various investigator-sponsored trials in indications, including first line and second line CML, acute myeloid leukemia, non-small cell lung cancer, and medullary thyroid cancer. In addition, its product pipeline consists of AP26113, an investigational inhibitor of anaplastic lymphoma kinase for treating advanced solid tumors comprising non-small cell lung cancer; and Ridaforolimus, an investigational mTOR inhibitor for various types of cancers. The company sells and markets Iclusig through specialty pharmacies and specialty distributors in the United States. It has collaboration and license agreement with Merck & Co., Inc. for the development, manufacture, and commercialization of ridaforolimus for use in cancer; and license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

307 Employees
Last Reported Date: 03/3/14
Founded in 1991

ariad pharmaceuticals inc (APS) Top Compensated Officers

Principal Founder, Chairman, Chief Executive ...
Total Annual Compensation: $749.8K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $465.4K
President of Research & Development and Chief...
Total Annual Compensation: $492.4K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $679.0K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $427.3K
Compensation as of Fiscal Year 2013.

ariad pharmaceuticals inc (APS) Key Developments

Ariad Pharmaceuticals Inc. Announces Resignation of Robert M. Whelan, Jr. as Director, Member of the Audit Committee and the Compensation Committee, Effective October 1, 2014

Ariad Pharmaceuticals Inc. announced that on September 13, 2014, Robert M. Whelan, Jr. notified the company that he will resign from the company's Board of Directors, effective October 1, 2014. Mr. Whelan has served as a director since April 2010 and currently serves as a member of the Audit Committee and the Compensation Committee.

Ariad Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Reaffirms Cash Flow Guidance for 2014

Ariad Pharmaceuticals Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. Total revenue for the quarter ended June 30, 2014 was $12.1 million against $14.01 million a year ago. Net loss for the quarter ended June 30, 2014 was $56.9 million, or $0.30 per share, compared to net loss of $69.0 million, or $0.37 per share, for the same period in 2013. For the six months, total revenue was $23,895,000 and net loss was $106,743,000 or $0.57 per basic and diluted share against total revenue of $20,476,000 and net loss of $133,655,000 or $0.74 per basic and diluted share for the same period a year ago. Net cash used in operating activities was $95,016,000 against $114,144,000 a year ago. The company anticipates cash used in operations in 2014 to range from $165 million to $175 million, unchanged from prior guidance.

Ariad Pharmaceuticals Inc. Presents at Citi's 9th Annual Biotech Conference, Sep-03-2014

Ariad Pharmaceuticals Inc. Presents at Citi's 9th Annual Biotech Conference, Sep-03-2014 . Venue: The Mandarin Oriental Boston, 776 Boylston Street, Boston, MA 02119, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
APS:GR €4.52 EUR +0.045

APS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arena Pharmaceuticals Inc $4.16 USD -0.11
Array BioPharma Inc $3.76 USD -0.03
CTI BioPharma Corp $2.68 USD +0.02
Insys Therapeutics Inc $33.71 USD -0.36
Pfizer Ltd/India 1,663 INR -24.80
View Industry Companies
 

Industry Analysis

APS

Industry Average

Valuation APS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 22.0x
Price/Book 8.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARIAD PHARMACEUTICALS INC, please visit www.ariad.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.